Management of Community-Onset Bacteremia
For community-onset bacteremia, empiric therapy should cover both Gram-positive organisms (including MRSA in high-prevalence settings) with vancomycin or daptomycin, and Gram-negative organisms with a beta-lactam or fluoroquinolone based on local susceptibility patterns, with treatment duration of 7 days for uncomplicated cases achieving source control and clinical stability, or 14 days minimum for complicated cases including MRSA bacteremia.
Empiric Antibiotic Regimen
Gram-Positive Coverage
- Vancomycin is the first-line empiric agent in healthcare settings with increased MRSA prevalence 1
- Alternative: Daptomycin 6 mg/kg IV daily (some experts recommend 8-10 mg/kg for complicated cases) 1
- Critical caveat: Linezolid should NOT be used for empirical therapy in suspected but unproven bacteremia 2
Gram-Negative Coverage
- Base selection on local antimicrobial susceptibility data and illness severity 2
- Optimal susceptibility threshold: Empiric antibiotics should have 80-89% susceptibility against local pathogens; critically ill patients may require ≥90% susceptibility 3
- Options include:
- Fourth-generation cephalosporins
- Carbapenems
- Beta-lactam/beta-lactamase combinations
- Fluoroquinolones (if local E. coli resistance <10-20%) 4
Special Considerations
- Neutropenic patients or severe sepsis: Add empiric coverage for multidrug-resistant Gram-negatives including Pseudomonas 2
- Femoral catheter-related infection in critically ill: Include empiric antifungal coverage (echinocandin or fluconazole) 2
- Recent antibiotic exposure or healthcare contact: Broader coverage warranted given higher resistance risk 5, 6
Duration of Therapy
Uncomplicated Bacteremia (7 Days)
Criteria for uncomplicated bacteremia 1, 7:
- Exclusion of endocarditis
- No implanted prostheses
- Follow-up blood cultures at 2-4 days negative
- Defervescence within 72 hours of effective therapy
- No metastatic infection sites
- Adequate source control achieved
Evidence: A landmark noninferiority trial demonstrated 7 days was noninferior to 14 days for uncomplicated Gram-negative bacteremia with clinical stability 8. This applies when patients are afebrile and hemodynamically stable for ≥48 hours 8, 9.
Complicated Bacteremia (14 Days to 4-6 Weeks)
- MRSA bacteremia: Minimum 14 days; 4-6 weeks if persistent bacteremia after 72 hours or complications present 1, 7, 10
- Staphylococcus aureus with any complication: 4-6 weeks 11, 10
- Endocarditis: 6 weeks 1, 7
- Candida fungemia: Minimum 14 days after first negative blood culture 11
Key Principle
Day 1 of therapy duration = first day of negative blood cultures 2
Source Control Measures
Mandatory Actions
- Clinical assessment to identify infection source and extent with elimination/debridement of other infection sites 1, 7
- Repeat blood cultures at 2-4 days after initial positive cultures and as needed to document clearance 1, 7
- Echocardiography for all adult patients with S. aureus bacteremia (TEE preferred over TTE) 7
Catheter Management
Remove catheter immediately if 11, 10:
- Fungi (yeasts or molds)
- Non-tuberculous mycobacteria
- Bacillus species
- Corynebacterium jeikeium
- Staphylococcus aureus
- Acinetobacter
- Pseudomonas aeruginosa
- Stenotrophomonas maltophilia
- Vancomycin-resistant Enterococcus
Catheter salvage possible with antibiotics alone 11:
- Coagulase-negative Staphylococcus (70-80% success rate)
- Consider antibiotic lock therapy for salvage attempts 2
If catheter retained: Remove if same bacteria identified in consecutive blood cultures at 48-72 hours despite appropriate antibiotics, or if patient clinically unstable 11
De-escalation Strategy
Timing and Approach
- De-escalation occurred in 84% of cases in recent ED sepsis cohorts 5
- Median time to discontinuation 5:
- MRSA coverage (vancomycin): 2 days
- Atypical coverage: 2 days
- Pseudomonas coverage: 4 days
Antimicrobial Stewardship
- Do NOT add gentamicin or rifampin to vancomycin for uncomplicated MRSA bacteremia or native valve endocarditis 1, 7
- Transition from empiric "Watch" group antibiotics to "Access" group when susceptibilities allow 12
- Procalcitonin-guided therapy: Consider using procalcitonin plus clinical evaluation to guide discontinuation when optimal duration unclear 13
Common Pitfalls
- Overtreatment with vancomycin: 70.6% guideline adherence in one study, with deviation primarily from unnecessary vancomycin without MRSA risk factors 5
- Inadequate empiric coverage: 13.7% received ineffective empiric therapy, with median 24 hours to effective antibiotics 5
- Prolonged therapy without indication: Recent evidence supports shorter courses (7 days) for uncomplicated cases, even in neutropenic patients 14, 8
- Missing source control: Failure to remove infected catheters or drain abscesses significantly worsens outcomes 1, 7
- Inadequate follow-up cultures: Must document clearance at 2-4 days to classify as uncomplicated 1
Monitoring for Complications
Indications for valve replacement surgery in endocarditis 7:
- Vegetation >10 mm
- Embolic event during first 2 weeks
- Severe valvular insufficiency
- Valvular perforation/dehiscence
- Decompensated heart failure
- Perivalvular/myocardial abscess
- New heart block
- Persistent fever or bacteremia